Literature DB >> 25938302

The Patient Protection and Affordable Care Act and Chronic Neurological Illnesses: Benefits and Challenges.

Gregory J Esper1, Daniel Hartung2, Orly Avitzur3.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25938302     DOI： 10.1001/jamaneurol.2015.0273

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN： 2168-6149            Impact factor:   18.302


× No keyword cloud information.
  5 in total

Review 1.  Considerations in the development of generic disease therapies for multiple sclerosis.

Authors:  Le H Hua; Jeffrey A Cohen
Journal:  Neurol Clin Pract       Date:  2016-08

2.  Care of persons with MS in clinical practice: Management by majority.

Authors:  Ruth Ann Marrie; Michael K Racke
Journal:  Neurol Clin Pract       Date:  2016-08

Review 3.  Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA.

Authors:  Daniel M Hartung
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

4.  Practices of US health insurance companies concerning MS therapies interfere with shared decision-making and harm patients.

Authors:  Dennis N Bourdette; Daniel M Hartung; Ruth H Whitham
Journal:  Neurol Clin Pract       Date:  2016-04

Review 5.  Health economics of disease-modifying therapy for multiple sclerosis in the United States.

Authors:  Daniel M Hartung
Journal:  Ther Adv Neurol Disord       Date:  2021-02-17       Impact factor: 6.570
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.